SETTING: Gaborone, Botswana. OBJECTIVE: To determine if starting anti-tuberculosis treatment at clinics in Gaborone without co-located human immunodeficiency virus (HIV) clinics would delay time to highly active antiretroviral therapy (HAART) initiation and be associated with lower survival compared to starting anti-tuberculosis treatment at clinics with on-site HIV clinics. DESIGN: Retrospective cohort study. Subjects were HAART-naïve, aged ≥ 21 years with pulmonary tuberculosis (TB), HIV and CD4 counts ≤ 250 cells/mm(3) initiating anti-tuberculosis treatment between 2005 and 2010. Survival at completion of anti-tuberculosis treatment or at 6 months post-treatment initiation and time to HAART after anti-tuberculosis treatment initiation were compared by clinic type. RESULTS: Respectively 259 and 80 patients from clinics without and with on-site HIV facilities qualified for the study. Age, sex, CD4, baseline sputum smears and loss to follow-up rate were similar by clinic type. Mortality did not differ between clinics without or with on-site HIV clinics (20/250, 8.0% vs. 8/79, 10.1%, relative risk 0.79, 95%CI 0.36-1.72), nor did median time to HAART initiation (respectively 63 and 66 days, P = 0.53). CONCLUSION: In urban areas where TB and HIV programs are separate, geographic co-location alone without further integration may not reduce mortality or time to HAART initiation among co-infected patients.
SETTING:Gaborone, Botswana. OBJECTIVE: To determine if starting anti-tuberculosis treatment at clinics in Gaborone without co-located human immunodeficiency virus (HIV) clinics would delay time to highly active antiretroviral therapy (HAART) initiation and be associated with lower survival compared to starting anti-tuberculosis treatment at clinics with on-site HIV clinics. DESIGN: Retrospective cohort study. Subjects were HAART-naïve, aged ≥ 21 years with pulmonary tuberculosis (TB), HIV and CD4 counts ≤ 250 cells/mm(3) initiating anti-tuberculosis treatment between 2005 and 2010. Survival at completion of anti-tuberculosis treatment or at 6 months post-treatment initiation and time to HAART after anti-tuberculosis treatment initiation were compared by clinic type. RESULTS: Respectively 259 and 80 patients from clinics without and with on-site HIV facilities qualified for the study. Age, sex, CD4, baseline sputum smears and loss to follow-up rate were similar by clinic type. Mortality did not differ between clinics without or with on-site HIV clinics (20/250, 8.0% vs. 8/79, 10.1%, relative risk 0.79, 95%CI 0.36-1.72), nor did median time to HAART initiation (respectively 63 and 66 days, P = 0.53). CONCLUSION: In urban areas where TB and HIV programs are separate, geographic co-location alone without further integration may not reduce mortality or time to HAART initiation among co-infectedpatients.
Authors: Mariana Posse; Filip Meheus; Henri van Asten; Andre van der Ven; Rob Baltussen Journal: Trop Med Int Health Date: 2008-05-06 Impact factor: 2.622
Authors: R E Chaisson; H C Clermont; E A Holt; M Cantave; M P Johnson; J Atkinson; H Davis; R Boulos; T C Quinn; N A Halsey Journal: Am J Respir Crit Care Med Date: 1996-10 Impact factor: 21.405
Authors: Christopher J Hoffmann; Katherine L Fielding; Victoria Johnston; Salome Charalambous; Craig Innes; Richard D Moore; Richard E Chaisson; Alison D Grant; Gavin J Churchyard Journal: J Acquir Immune Defic Syndr Date: 2011-11-01 Impact factor: 3.731
Authors: Sawsan Elbireer; David Guwatudde; Peter Mudiope; Juliet Nabbuye-Sekandi; Yukari C Manabe Journal: Trop Med Int Health Date: 2011-05-18 Impact factor: 2.622
Authors: Marianne A B van der Sande; Maarten F Schim van der Loeff; Rachel C Bennett; Mary Dowling; Akum A Aveika; Toyin O Togun; Saihou Sabally; David Jeffries; Richard A Adegbola; Ramu Sarge-Njie; Assan Jaye; Tumani Corrah; Samuel McConkey; Hilton C Whittle Journal: AIDS Date: 2004-09-24 Impact factor: 4.177
Authors: Nicola M Zetola; Nenad Macesic; Sanghyuk S Shin; Sanghyuk Shin; Alexandra Peloso; Ronald Ncube; Jeffrey D Klausner; Chawangwa Modongo; Ronald G Collman Journal: BMC Infect Dis Date: 2014-07-22 Impact factor: 3.090
Authors: Michael E Herce; Jill Morse; Dora Luhanga; Jennifer Harris; Helene J Smith; Stable Besa; Graham Samungole; Nzali Kancheya; Monde Muyoyeta; Stewart E Reid Journal: BMC Infect Dis Date: 2018-10-26 Impact factor: 3.090